Literature DB >> 21309877

Early functional echocardiogram and inhaled nitric oxide: usefulness in managing neonates born following extreme preterm premature rupture of membranes (PPROM).

Dharmesh M Shah1, Martin Kluckow.   

Abstract

AIM: Poor neonatal outcome of preterm premature rupture of membranes (PPROM) < 24 weeks' gestational age (GA) is probably a result of abnormalities in both airway and vascular developments, ventilation perfusion mismatch, and possibly persistent pulmonary hypertension of the newborn (PPHN). Perinatal mortality of 50-90% has been reported in the past, with recent literature reporting significant improvement in neonatal survival. We report our 8-year experience in this group of infants using early diagnostic functional echocardiography (fECHO), high-frequency ventilation (HFV) and inhaled nitric oxide (iNO).
METHODS: The obstetric and neonatal databases were searched to identify babies with PPROM (< 20 weeks' gestation) or rupture earlier than 25 weeks for more than 14 days.
RESULTS: Twenty-six infants were identified, of whom 20 were admitted to the neonatal intensive care unit (NICU; mean GA 27.8 weeks, mean birth weight (BW) 1207 g). Early echocardiographic data were available in 12/15 infants requiring mechanical ventilation of whom 10 had evidence of PPHN. All infants who received iNO therapy survived to discharge and only two infants died. Survival to discharge was 69% for the whole cohort of infants and 90% for infants admitted to the NICU. In contrast, for the cohort from pre-iNO and -HFV era, the overall survival to discharge was 62% and 66% for the infants admitted to the NICU.
CONCLUSION: Premature infants with PPROM and presumed severe hypoxemic respiratory failure because of hypoplastic lungs often have significant PPHN and may show improvement in oxygenation after treatment with HFV and iNO. Early fECHO results in earlier identification and treatment of infants with PPHN in this high-risk group.
© 2011 The Authors. Journal of Paediatrics and Child Health © 2011 Paediatrics and Child Health Division (Royal Australasian College of Physicians).

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21309877     DOI: 10.1111/j.1440-1754.2010.01982.x

Source DB:  PubMed          Journal:  J Paediatr Child Health        ISSN: 1034-4810            Impact factor:   1.954


  7 in total

1.  Association of Early Inhaled Nitric Oxide With the Survival of Preterm Neonates With Pulmonary Hypoplasia.

Authors:  Kevin R Ellsworth; Marc A Ellsworth; Amy L Weaver; Kristin C Mara; Reese H Clark; William A Carey
Journal:  JAMA Pediatr       Date:  2018-07-02       Impact factor: 16.193

2.  Treatment of premature infants with pulmonary hypertension and right ventricular dysfunction with milrinone: a case series.

Authors:  A T James; C Bee; J D Corcoran; P J McNamara; O Franklin; A F El-Khuffash
Journal:  J Perinatol       Date:  2014-11-27       Impact factor: 2.521

Review 3.  Management of hypoxemic respiratory failure and pulmonary hypertension in preterm infants.

Authors:  N Ambalavanan; J L Aschner
Journal:  J Perinatol       Date:  2016-06       Impact factor: 2.521

4.  The evolution of cardiac point of care ultrasound for the neonatologist.

Authors:  Yogen Singh; Shazia Bhombal; Anup Katheria; Cecile Tissot; María V Fraga
Journal:  Eur J Pediatr       Date:  2021-06-14       Impact factor: 3.183

5.  Use of sildenafil in an infant with persistent pulmonary hypertension secondary to lung and renal hypoplasia - a case report.

Authors:  Karen Lavie-Nevo; Kevin C Harris; Joseph Y Ting
Journal:  BMC Pediatr       Date:  2019-11-06       Impact factor: 2.125

6.  Preterm infant outcomes in relation to the gestational age of onset and duration of prelabour rupture of membranes: a retrospective cohort study.

Authors:  Pramod Pharande; Abdel-Latif Mohamed; Barbara Bajuk; Kei Lui; Srinivas Bolisetty
Journal:  BMJ Paediatr Open       Date:  2017-12-29

7.  Factors influencing decision making in neonatology: inhaled nitric oxide in preterm infants.

Authors:  Veena Manja; Gordon Guyatt; Satyan Lakshminrusimha; Susan Jack; Haresh Kirpalani; John A F Zupancic; Dmitry Dukhovny; John J You; Sandra Monteiro
Journal:  J Perinatol       Date:  2018-10-23       Impact factor: 2.521

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.